Systematic benefit-risk assessment for buprenorphine implant: a semiquantitative method to support risk management.
Vicki OsborneMiranda DaviesDebabrata RoyFrancesco TescioneSaad A W ShakirPublished in: BMJ evidence-based medicine (2020)
The benefit-risk profile of buprenorphine implant is considered favourable in comparison to sublingual buprenorphine, based on this semiquantitative analysis using available data. Further data from real-world use on benefits and risks should be used for ongoing monitoring of the benefit-risk profile of buprenorphine implants in the postmarketing setting.